Table 1 Basic demographic characterization of the patient population

From: Network analysis of extraintestinal manifestations and associated autoimmune disorders in Crohn’s disease and ulcerative colitis

Disease type

 

Crohn’s disease

 

Ulcerative colitis

 

IBDU

 

IBD Total(CD + UC + IBDU)

 

UC vs. CD

  

Total

N = 15,924

 

Total

N = 11,718

 

Total

N = 2692

 

Total

N = 30,334

 

p value ≤ 

Sex

 

14,806

 

10,476

 

1663

 

26,945

  
  

n

%

n

%

n

%

n

%

 

Male

 

6805

45.961

5401

51.556

828

49.790

13,034

48.373

0.00001

Female

 

8001

54.039

5075

48.444

835

50.210

13,911

51.627

0.00001

AGE [years]

 

14,806

 

10,476

 

1663

 

26,945

  

Age (at first encounter)

 

Median

IQR

Median

IQR

Median

IQR

Median

IQR

 
  

40

25.000

40

25.000

44

27.000

40

25.000

0.00001

Age groups (at first encounter)

 

n

%

n

%

n

%

n

%

 

Children and adolescents [<18 years]

 

1133

7.652

651

6.214

59

3.548

1843

6.840

0.00001

Adults [18–64 years]

 

12,471

84.229

8784

83.849

1354

81.419

22,609

83.908

0.4250

Seniors [>64 years]

 

1202

8.118

1041

9.937

250

15.033

2493

9.252

0.00001

Disease features and complications

Fistulas

Fissure and fistula of anal and rectal regions

K60

0

0.000

0

0.000

0

0.000

0

0.000

0.00001

Acute anal fissure

K60.0

55

0.345

24

0.205

5

0.186

84

0.277

0.0404

Chronic anal fissure

K60.1

78

0.490

31

0.265

9

0.334

118

0.389

0.0043

Anal fissure. unspecified

K60.2

909

5.708

400

3.414

99

3.678

1408

4.642

0.00001

Anal fistula

K60.3

1342

8.428

180

1.536

80

2.972

1602

5.281

0.00001

Rectal fistula

K60.4

258

1.620

19

0.162

10

0.371

287

0.946

0.00001

Anorectal fistula

K60.5

80

0.502

10

0.085

7

0.260

97

0.320

0.00001

Fistula of intestine

K62.3

61

0.383

68

0.580

18

0.669

147

0.485

0.0221

Fistulae involving female genital tract

N82

0

0.000

0

0.000

0

0.000

0

0.000

0.00001

Fistula of vagina to small intestine

N82.2

15

0.094

4

0.034

4

0.149

23

0.076

0.0988

Fistula of vagina to large intestine

N82.3

251

1.576

32

0.273

13

0.483

296

0.976

0.00001

Other female intestinal-genital tract fistula.

N82.4

57

0.358

11

0.094

7

0.260

75

0.247

0.00001

Vesicointestinal fistula

K82.3

4

0.025

1

0.009

0

0.000

5

0.016

0.5750

Number of patients with Fistulas

 

2350

14.758

675

5.760

206

7.652

3231

10.651

0.00001

Abscesses

Abscess of anal and rectal regions

K61

0

0.000

0

0.000

0

0.000

0

0.000

0.00001

Anal abscess

K61.0

1246

7.825

225

1.920

75

2.786

1546

5.097

0.00001

Rectal abscess

K61.1

485

3.046

97

0.828

35

1.300

617

2.034

0.00001

Anorectal abscess

K61.2

119

0.747

26

0.222

9

0.334

154

0.508

0.00001

Ischiorectal abscess

K61.3

484

3.039

93

0.794

30

1.114

607

2.001

0.00001

Number of patients with Abscesses

 

1496

9.395

308

2.628

101

3.752

1905

6.280

0.00001

Obstructive complications

Paralytic ileus and intestinal obstruction without hernia

K56

0

0.000

0

0.000

0

0.000

0

0.000

0.00001

Paralytic ileus

K56.0

59

0.371

25

0.213

10

0.371

94

0.310

0.0254

Intussusception

K56.1

39

0.245

15

0.128

6

0.223

60

0.198

0.0416

Volvulus

K56.2

98

0.615

47

0.401

14

0.520

159

0.524

0.0186

Other impaction of intestine

K56.4

81

0.509

31

0.265

12

0.446

124

0.409

0.0022

Intestinal adhesions [bands] with obstruction

K56.5

759

4.766

198

1.690

55

2.043

1012

3.336

0.00001

Other and unspecified intestinal obstruction

K56.6

6306

39.601

1613

13.765

374

13.893

8293

27.339

0.00001

Ileus. unspecified

K56.7

590

3.705

232

1.980

80

2.972

902

2.974

0.00001

Number of patients with obstructive complications

 

6586

41.359

1804

15.395

438

16.270

8828

29.103

0.00001

Medication exposure

ATC-CODES

Conventional therapy

5-ASA (mesalazine/mesalamine)

A07EC02

6450

40.505

9241

78.862

1348

50.074

17039

56.171

0.00001

SASP (sulfasalazine) PO

A07EC01

635

3.988

549

4.685

88

3.269

1272

4.193

0.0051

Number of patients on conventional therapy

 

6782

42.590

9373

79.988

1385

51.449

17540

57.823

0.00001

Immunomodulators (antimetabolites)

Azathioprine

L04AX01

6353

39.896

2867

24.467

297

11.033

9517

31.374

0.00001

6-Mercaptopurine

L01BB02

351

2.204

136

1.161

10

0.371

497

1.638

0.00001

Methotrexate

L01BA01

2577

16.183

759

6.477

147

5.461

3483

11.482

0.00001

Methotrexate

L04AX03

80

0.502

28

0.239

9

0.334

117

0.386

0.0007

Number of patients on immunomodulators

 

8023

50.383

3353

28.614

419

15.565

11795

38.884

0.00001

Calcineurin inhibitors

Tacrolimus

D11AH01

649

4.076

389

3.320

68

2.526

1106

3.646

0.0012

Tacrolimus

L04AD02

77

0.484

78

0.666

23

0.854

178

0.587

0.0546

Cyclosporine

L04AD01

69

0.433

54

0.461

12

0.446

135

0.445

0.8039

Cyclosporine

S01XA18

156

0.980

124

1.058

24

0.892

304

1.002

0.5594

Number of patients on calcineurin inhibitors

 

911

5.721

617

5.265

115

4.272

1643

5.416

0.1072

Steroids

Prednisone

H02AB07

9152

57.473

6949

59.302

1174

43.611

17275

56.949

0.0024

Prednisolone

H02AB06

73

0.458

55

0.469

5

0.186

133

0.438

0.9659

Prednisolone

S01BA04

1466

9.206

1085

9.259

261

9.695

2812

9.270

0.8970

methylprednisolone

H02AB04

824

5.175

612

5.223

139

5.163

1575

5.192

0.8801

Budesonide

A07EA06

3960

24.868

1835

15.660

382

14.190

6177

20.363

0.00001

Hydrocortisone

A07EA02

750

4.710

2747

23.443

183

6.798

3680

12.132

0.00001

Hydrocortisone

D07AA02

3097

19.449

2149

18.339

504

18.722

5750

18.956

0.0210

Hydrocortisone

D07XA01

139

0.873

102

0.870

20

0.743

261

0.860

0.9650

Hydrocortisone

H02AB09

2143

13.458

982

8.380

115

4.272

3240

10.681

0.00001

Number of patients on Steroids

 

12,162

76.375

8914

76.071

1745

64.822

22821

75.232

0.5665

JAK inhibitors

Tofacitinib

L04AA29

21

0.132

135

1.152

10

0.371

166

0.547

0.00001

Biologics

Anti-TNF

Infliximab

L04AB02

4179

26.243

2049

17.486

190

7.058

6418

21.158

0.00001

Adalimumab

L04AB04

3919

24.611

988

8.431

136

5.052

5043

16.625

0.00001

Golimumab

L04AB06

133

0.835

168

1.434

19

0.706

320

1.055

0.00001

Certolizumab pegol

L04AB05

19

0.119

6

0.051

3

0.111

28

0.092

0.0971

Anti-IL12/23

Ustekinumab

L04AC05

1617

10.154

184

1.570

41

1.523

1842

6.072

0.00001

Anti-integrin

Vedolizumab

L04AA33

533

3.347

596

5.086

39

1.449

1168

3.850

0.00001

Number of patients on Biologics

 

7667

48.147

3081

26.293

332

12.333

11080

36.527

0.00001

Healthcare utilization

Average number of hospitalizations per patient per year

 

0.231851294

 

0.185782557

 

0.20690936

 

0.2118415

 

0.000001

Average number of ER visits per patient per year

 

3.902599849

 

2.971070148

 

3.12667162

 

3.47389068

 

0.00001

Average number of hospitalizations & ER visits per patient per year

 

4.134451143

 

3.156852705

 

3.33358098

 

3.68573218

 

0.00001